WO2002060387A2 - Use of prostaglandin analogs for treatment of cardiac conditions - Google Patents
Use of prostaglandin analogs for treatment of cardiac conditions Download PDFInfo
- Publication number
- WO2002060387A2 WO2002060387A2 PCT/US2002/003103 US0203103W WO02060387A2 WO 2002060387 A2 WO2002060387 A2 WO 2002060387A2 US 0203103 W US0203103 W US 0203103W WO 02060387 A2 WO02060387 A2 WO 02060387A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pgf
- composition
- treatment
- analogs
- cardiac
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Definitions
- the invention is in the field of treatment for cardiac associated conditions such as chronic heart failure and cardiac hypertrophy.
- cardiac associated conditions such as chronic heart failure and cardiac hypertrophy.
- it concerns the use of prostaglandin analogs to ameliorate such conditions.
- prostaglandin F analogs typified by unoprostone isopropyl
- These compounds have been shown, in particular, to have a vasorelaxant effect on preconstricted pig retinal arterioles in an in vitro model.
- the arterioles were preconstricted with endothelin (ET-1).
- ET-1 endothelin
- unoprostone isopropyl was able to inhibit vaso constriction in the choroidal vessels. See, for example, Paterson, C.A., Am. Acad. Ophthalmol, Symposium Abstracts pp. 11-12.
- ET-1 and its associated receptors have been implicated in vascular conditions other than those occurring in the eye.
- Love, M.P., et al, Clin. Sci. (Colch) (2000) 98:65-70 showed that administration of ET-1 or sarafotoxin S6C (a selective ETB receptor agonist) resulted in constriction of the dorsal hand vein, both in patients with chronic heart failure and in healthy subjects, although response to ET-1 or sarafotoxin S6C (a selective ETB receptor agonist)
- ET-1 was blunted in heart failure patients as compared to normals. Further, Wolf, S.C., et al, Nephrol Dial. Transplant (1999) 14 Suppl. 4:29-30 showed that ET-1 was involved in the patho genesis of uraemic cardiac hypertrophy and renal failure in rats. In this study, the authors suggest that ET receptor antagonists may provide a therapeutic group for cardiac hypertrophy and renal protein excretion.
- prostaglandin F analogs such as those described in U.S. patent 5,221 ,763 and illustrated by unoprostone isopropyl ester, which is marketed under the name Rescula for the treatment of glaucoma, are also useful in ameliorating conditions associated with cardiac problems, including atherosclerosis, myocardial infarction, chronic heart failure and the like. These analogs do not have binding affinity to prostaglandin receptors, but are similar in structure to PGF 2 ⁇ .
- the invention is directed to methods to treat conditions of the cardiovascular system, especially those associated with vaso constriction, which method comprises administering to a subject in need of such treatment an effective amount of a PGF 2 ⁇ analog which fails to bind substantially to prostaglandin receptors.
- Systemic administration of the PGF 2 ⁇ analogs is greatly preferred and thus, formulations suitable for systemic administration constitute an additional aspect of the invention.
- the invention is directed to treating conditions of the cardiovascular system in humans and other animals by administering PGF 2 ⁇ analogs which do not bind prostaglandin receptors in a substantial degree.
- PGF analogs is specifically defined to include only those docosanoid structures analogous to PGF that have no substantial affinity for prostaglandin receptors or FP receptors or other receptors associated with glaucoma. These compounds, however, are able to prevent and reverse ET-1 induced vasoconstriction.
- PGF analogs of these analogs are set forth in U.S. patent 5,221,763, the contents of which are incorporated herein by reference.
- the most preferred form of such PGF analogs is the compound 13,14-dihydro-15-keto-20-ethyl PGF 2 ⁇ .
- Particularly preferred is the isopropyl ester, although additional esters such as the ethyl, n-propyl, and hexyl esters are included within the scope of the invention.
- the PGF analogs of the invention are useful in the treatment of cardiac conditions as further described below.
- treat or “treatment” is meant both prevention and therapeutic administration of the compounds in question.
- prevention or “prevent” is meant that the treatment is administered prophylactically and ameliorates any subsequent development of the undesired condition. It specifically does not necessarily mean that the condition is completely precluded or not subsequently detected.
- the word “prevention” has the more conventional meaning that the severity of the condition is ameliorated as compared to its intensity absent the treatment designed to "prevent” it.
- the PGF analogs of the invention may be used to treat cardiac conditions alone, or in combination with additional therapeutic compounds. Two or more PGF analogs may be used in a protocol for treatment. If a single PGF analog is used in combination with an additional PGF analog and/or in combination with an additional pharmaceutical, the administration may be simultaneous or sequential in any order.
- the design of practical protocols for administration of the PGF analogs useful in the invention is a matter of routine optimization readily conducted by the practitioner.
- the PGF analogs may be used to treat cardiac conditions in human subjects as well as in veterinary subjects and in laboratory contexts.
- the dosage suitable for administration is dependent on the nature of the subject, the route of administration, and the severity of the condition, as well as the judgment of the practitioner. Typical dosage amounts are in the range of 0.01-50 mg/kg, preferably 0.1-10 mg/kg. However, the dosage range may vary widely and include dosages outside the specified range, again, depending on the specific conditions encountered.
- Suitable conditions susceptible to treatment using the PGF analogs of the invention include uraemic cardiac hypertrophy, chronic heart failure, intimal hyperplasia, pulmonary hypertension, myocardial infarctions, including acute and sub-acute forms, atherosclerosis, congestive heart failure, and hypertension in general.
- systemic administration is preferred.
- Such administration may be by injection, including, without limitation, intravenous, intramuscular, intraperitoneal and subcutaneous injection; it may be by means of a transdermal patch or lotion; it may be by transmucosal delivery, such as an intranasal spray or suppository.
- Administration may also be through an oral route or the PGF analogs may be delivered by a sustained release formulation or osmotic pump. Any mode of administration which is effective to provide the active ingredient systemically is suitable and many such means are known in the art.
- the PGF analogs of the invention will be formulated according to the mode of administration. Such formulations are well known in the art and can be found, for example, in Remington's Pharmaceutical Sciences, latest edition, Mack Publishing Co., Easton, PA, incorporated herein by reference.
- the preferred oral route of administration can be by, for example, tablets, capsules, powders, syrups, and the like.
- Formulations for transdermal or transmucosal administration require penetrants such as are known in the art. Methods of formulation amenable to these routes of administration are well within ordinary skill.
- the formulations will contain the active ingredient(s) in varying percentages depending on the nature of the formulation, typically between 0.5 and 95% of the composition, more commonly on the order of 20-50% of the composition wt/wt.
- Suitable excipients include those conventional in the art such as buffers, fillers, antioxidants, and other preservatives.
- cardiac conditions are readily susceptible to amelioration by or prevention by the method of the invention which comprises administering at least one PGF analog to a subject in need of such treatment.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2002243795A AU2002243795A1 (en) | 2001-01-30 | 2002-01-30 | Use of prostaglandin analogs for treatment of cardiac conditions |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26526201P | 2001-01-30 | 2001-01-30 | |
US60/265,262 | 2001-01-30 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002060387A2 true WO2002060387A2 (en) | 2002-08-08 |
WO2002060387A3 WO2002060387A3 (en) | 2003-03-06 |
Family
ID=23009718
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2002/003103 WO2002060387A2 (en) | 2001-01-30 | 2002-01-30 | Use of prostaglandin analogs for treatment of cardiac conditions |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2002243795A1 (en) |
WO (1) | WO2002060387A2 (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5221763A (en) * | 1987-04-30 | 1993-06-22 | R-Tech Ueno, Ltd. | Prostaglandins of the F series |
US6211233B1 (en) * | 1997-06-19 | 2001-04-03 | Nicox S.A. | Prostaglandin pharmaceutical compositions |
US6235781B1 (en) * | 1998-07-14 | 2001-05-22 | Alcon Laboratories, Inc. | Prostaglandin product |
US6329426B1 (en) * | 1997-10-13 | 2001-12-11 | R-Tech Ueno, Ltd. | Method for treating ocular hypertension of glaucoma |
-
2002
- 2002-01-30 WO PCT/US2002/003103 patent/WO2002060387A2/en not_active Application Discontinuation
- 2002-01-30 AU AU2002243795A patent/AU2002243795A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5221763A (en) * | 1987-04-30 | 1993-06-22 | R-Tech Ueno, Ltd. | Prostaglandins of the F series |
US6211233B1 (en) * | 1997-06-19 | 2001-04-03 | Nicox S.A. | Prostaglandin pharmaceutical compositions |
US6329426B1 (en) * | 1997-10-13 | 2001-12-11 | R-Tech Ueno, Ltd. | Method for treating ocular hypertension of glaucoma |
US6235781B1 (en) * | 1998-07-14 | 2001-05-22 | Alcon Laboratories, Inc. | Prostaglandin product |
Also Published As
Publication number | Publication date |
---|---|
AU2002243795A1 (en) | 2002-08-12 |
WO2002060387A3 (en) | 2003-03-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6384034B2 (en) | Method of treating migraines and pharmaceutical compositions | |
US6245789B1 (en) | HIV and viral treatment | |
JPH0748280A (en) | Composition for multiplicative medical treatment | |
JPH09505809A (en) | Inhibition of smooth muscle migration and proliferation by hydroxycarbazole compounds | |
CA2415577C (en) | Use of cox-2 inhibitors for preventing immunodeficiency | |
RU2003136077A (en) | USE OF COMPOUNDS HAVING JOINT INHIBITING ACTIVITY AGAINST NEP (NEUTRAL ENDOPEPTIDASE) AND MR (METALLOPROTEASE) FOR THE PREPARATION OF MEDICINES | |
JP2002537258A5 (en) | ||
AU2002350832B2 (en) | Use of irbesartan for the preparation of medicaments that are used to prevent or treat pulmonary hypertension | |
JP2008044871A (en) | Cardiovascular disease-preventing and treating agent | |
WO2002060387A2 (en) | Use of prostaglandin analogs for treatment of cardiac conditions | |
US6462021B1 (en) | Use of low molecular weight thrombin inhibitor | |
EA200100869A1 (en) | CRYSTALLINE FORM Eplerenone | |
Chrysant et al. | Comparison of moexipril, a new ACE inhibitor, to verapamil-SR as add-on therapy to low dose hydrochlorothiazide in hypertensive patients | |
AU2001225625A1 (en) | Use of melagatran for manufacture of a medicament for the treatment of ischemic disorders | |
JPH10513186A (en) | Combination therapy of HIV infection using the HIV protease inhibitor indinavir and the reverse transcriptase inhibitor 3TC, optionally with AZT, DDI or DDC | |
JP4783887B2 (en) | Pharmaceutical composition for inhibiting damage of myocardial tissue | |
JP4737686B2 (en) | New medicine | |
JPH09255589A (en) | Stress suppressant | |
Hansson | How far should we lower blood pressure in the elderly | |
AU2009327374A1 (en) | Treatment of major adverse cardiac events and acute coronary syndrome using secretory phospholipase A2 (sPLA2) inhibitor or sPLA2 inhibitor combination therapies | |
KR20050072480A (en) | Use of fosinopril to reduce cardiovascular events in dialysis patients | |
KR960033468A (en) | Treatment of Acute Myocardial Infarction with Hirudin and Acetylsalicylic Acid in Patients Without Thrombolytic Treatment | |
Akarsu et al. | Iloprost, a stable analogue of PGI2, potentiates the hyperthermic effect of PGE2 in rats | |
CA2353727C (en) | Use of amtolmetin guacyl for the production of anti-inflammatory drugs for intestinal inflammations | |
AU2001270902B2 (en) | Use of COX-2 inhibitors for preventing immunodeficiency |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase in: |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |